6533b7dbfe1ef96bd1270a1c

RESEARCH PRODUCT

CARDIOMETABOLIC SYNDROME AND SARCOPENIC OBESITY IN OLDER PERSONS

Ligia J. DominguezMario Barbagallo

subject

Gerontologymedicine.medical_specialtyAgingEndocrinology Diabetes and MetabolismPopulationAdipokineCardiometabolic syndromeInternal MedicinemedicineHumansSarcopenic obesityObesityeducationhealth care economics and organizationsAgedMetabolic Syndromeeducation.field_of_studybusiness.industryPublic healthType 2 Diabetes Mellitusmedicine.diseaseObesityMuscular AtrophyAdipose TissueCardiovascular DiseasesSarcopeniaLean body massPhysical therapyBody CompositionInflammation MediatorsInsulin ResistanceCardiology and Cardiovascular MedicinebusinessHuman

description

The aging of the world's population is a major contributor to the growing prevalence of the cardiometabolic syndrome (CMS) because older persons are more affected by the constellation of cardiovascular risk factors that constitute the syndrome. The prevalence of CMS has been related to the increasing prevalence of obesity, which is growing progressively even among older age groups. Indeed, obesity and aging are 2 overlapping mounting public health problems. It is currently accepted that CMS predicts cardiovascular mortality and/or the development of type 2 diabetes mellitus, and this is also true in studies including older persons. CMS is further complicated by modifications in body composition and fat redistribution during aging; older adults are at higher risk for developing central obesity and sarcopenia or sarcopenic obesity, a condition characterized by an important reduction in lean body mass associated with obesity, linked to an increased production of inflammatory adipokines that may alter insulin sensitivity and muscle mass and strength. A better understanding of the pathophysiologic mechanisms of sarcopenic obesity may help to elucidate the complex relationship between CMS and mortality/morbidity in older adults.

10.1111/j.1559-4564.2007.06673.xhttp://hdl.handle.net/10447/17546